Treatment of Thromboangiitis Obliterans Using Smoking Cessation and  Far-infrared Therapy: A Case Study

Case Report

Treatment of Thromboangiitis Obliterans Using Smoking Cessation and Far-infrared Therapy: A Case Study

Volume 63 - Issue 7 - July 2017 ISSN 1943-2720

Abstract

Thromboangiitis obliterans (Buerger’s disease) is a rare, nonatherosclerotic segmental inflammatory vasculitis that commonly involves small- and medium-sized vessels. Ischemic tenderness impairs patient quality of life and places patients at high risk for amputation. The only definitive known treatment is smoking cessation. Far-infrared (FIR) therapy has shown promising effects on blood flow and healing, but its use in patients with Buerger’s disease has not been reported.A 31-year-old man with a 15-pack-year history of smoking, no drug abuse, and no other significant medical history, trauma, or family history diagnosed with thromboangiitis obliterans presented for care at the authors’ clinic. Claudication with severe tenderness of both legs and an ischemic ulcer over the right big toe were noted. After surgical debridement of the devitalized tissue, the patient received FIR therapy (5–25 µm, peak at 8.2 µm) applied 25 cm above the surface of the ischemic wound for 40 minutes, 3 times per week. The patient also tapered his smoking. The wound started to heal; granulation tissue was evident and, after 8 weeks, the right lower extremities gradually rewarmed from 24˚ C to 28˚ C as measured on the dorsal foot. His pain level decreased from 8 to 5. FIR therapy was continued until the patient stopped smoking (8 months). At the 10-month follow-up visit, the wound had healed completely and resting pain had improved. The results of this case study suggest additional research to explore the potential effects of FIR on patients with thromboangiitis obliterans is warranted.

Introduction

Case Report

Discussion

Conclusion

Affiliations

Correspondence

References

1. Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med. 2000;343(12):864–869.

2. Arkkila PE. Thromboangiitis obliterans (Buerger’s disease). Orphanet J Rare Dis. 2006;01:14.

3. Piazza G, Creager MA. Thromboangiitis obliterans. Circulation. 2010;121(16):1858–1861.

4. Bashar K, Healy D, Browne LD, et al. Role of far infra-red therapy in dialysis arterio-venous fistula maturation and survival: systematic review and meta-analysis. PLoS One. 2014;9(8):e104931.

5. Lin CC, Yang WC, Chen MC, Liu WS, Yang CY, Lee PC. Effect of far infrared therapy on arteriovenous fistula maturation: an open-label randomized controlled trial. Am J Kidney Dis. 2013;62(2):304–311.

6. Huang PH, Chen JW, Lin CP, et al. Far infra-red therapy promotes ischemia-induced angiogenesis in diabetic mice and restores high glucose-suppressed endothelial progenitor cell functions. Cardiovasc Diabetol. 2012;11:99.

7. Li K, Zhang Z, Liu NF, et al. Efficacy and safety of far infrared radiation in lymphedema treatment: clinical evaluation and laboratory analysis. Lasers Med Sci. 2017;32(3):485–494.

8. Cooper LT, Tse TS, Mikhail MA, McBane RD, Stanson AW, Ballman KV. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger’s disease). J Am Coll Cardiol. 2004;44(12):2410–2411.

9. Cottencin O, Karila L, Lambert M, et al. Cannabis arteritis: review of the literature. J Addict Med. 2010;4(4):191–196.

10. Chen YW, Nagasawa T, Wara-Aswapati N, et al. Association between periodontitis and anti-cardiolipin antibodies in Buerger disease. J Clin Periodontol. 2009;36(10):830–835.

11. Lie JT. Diagnostic histopathology of major systemic and pulmonary vasculitic syndromes. Rheum Dis Clin North Am. 1990;16(2):269–292.

12. Adar R, Papa MZ, Halpern Z, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med. 1983;308(19):1113–1116.

13. Tamai H, Kobayashi M, Takeshita K, et al. Possible involvement of Notch signaling in the pathogenesis of Buerger’s disease. Surg Today. 2014;44(2):307–313.

14. Makita S, Nakamura M, Murakami H, Komoda K, Kawazoe K, Hiramori K. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger’s disease). Circulation. 1996;94(9 suppl):II211–II215.

15. Hus I, Sokolowska B, Walter-Croneck A, Chrapko M, Nowaczynska A, Dmoszynska A. Assessment of plasma prothrombotic factors in patients with Buerger’s disease. Blood Coagul Fibrinolysis. 2013;24(2):133–139.

16. Ohta T, Ishioashi H, Hosaka M, Sugimoto I. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004;39(1):176–180.

17. Dargon PT, Landry GJ. Buerger’s disease. Ann Vasc Surg. 2012;26(6):871–880.

18. Abeles AM, Nicolescu M, Pinchover Z, Abeles M. Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors. Vascular. 2014;22(4):313–316.

19. De Haro J, Acin F, Bleda S, Varela C, Esparza L. Treatment of thromboangiitis obliterans (Buerger’s disease) with bosentan. BMC Cardiovasc Disord. 2012;12:5.

20. Ikeda K, Yotsuyanagi T, Arai K, Suda T, Saito T, Ezoe K. Combined revascularization and free-tissue transfer for limb salvage in a Buerger disease patient. Ann Vasc Surg. 2012;26(3):422, e5–e8.

21. Kulkarni S, Kulkarni G, Shyam AK, Kulkarni M, Kulkarni R, Kulkarni V. Management of thromboangiitis obliterans using distraction osteogenesis: a retrospective study. Indian J Orthop. 2011;45(5):459–464.

22. Toyokawa H, Matsui Y, Uhara J, et al. Promotive effects of far-infrared ray on full-thickness skin wound healing in rats. Exp Biol Med. 2003;228(6):724–729.